EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway

Efficacy of Rechallenge Chemotherapy in Patients With Sensitive Relapsed Small Cell Lung Cancer

(2015) Kazushige Wakuda et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer

(2015) Masaru Matsumoto et al.   BMC CANCER

The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis

(2015) J. Lahtela et al.   Disease Models & Mechanisms

BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737

(2015) Danielle S. Potter et al.   NEOPLASIA

Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment

(2014) M. E. Vail et al.   CANCER RESEARCH

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

(2014) J S Ross et al.   JOURNAL OF CLINICAL PATHOLOGY

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

(2014) Shigeki Umemura et al.   Journal of Thoracic Oncology

EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme

(2013) Bryan W. Day et al.   CANCER CELL

A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3

(2013) Jenni Lahtela et al.   CELL CYCLE

Fragment-based drug design and identification of HJC0123 , a novel orally bioavailable STAT3 inhibitor for cancer therapy

(2013) Haijun Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic targeting of EPH receptors and their ligands

(2013) Andrew W. Boyd et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer Somatic Mutations Disrupt Functions of the EphA3 Receptor Tyrosine Kinase through Multiple Mechanisms

(2012) Erika M. Lisabeth et al.   BIOCHEMISTRY

Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling

(2012) Fabia Pancotti et al.   CELLULAR SIGNALLING

Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer

(2012) Guanglei Zhuang et al.   JNCI-Journal of the National Cancer Institute

Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3

(2011) Olga A. Guryanova et al.   CANCER CELL

Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma

(2011) H.-Q. Xi et al.   JOURNAL OF CLINICAL PATHOLOGY

Essential role of Stat3 in PI3K-induced oncogenic transformation

(2011) Jonathan R. Hart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PI3K and STAT3: A New Alliance

(2011) P. K. Vogt et al.   Cancer Discovery

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

(2010) K Schmid et al.   BRITISH JOURNAL OF CANCER

AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001

(2009) M. Marinov et al.   CLINICAL CANCER RESEARCH

Eph-Ephrin Bidirectional Signaling in Physiology and Disease

(2008) Elena B. Pasquale   CELL

Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine Kinase

(2008) Wei Bin Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE